Cardiovascular disease modelsTransverse Aortic Constriction (TAC) Mouse Model of Heart Failure

Test efficacy of novel heart failure treatments using the golden standard TAC Mouse Model

Home » Cardiovascular CRO Services » Transverse Aortic Constriction (TAC) Mouse Model of Heart Failure

TAC Mouse Model Characteristics

The transverse aortic constriction (TAC) mouse model is a surgical model of pressure overload-induced cardiac hypertrophy and associated heart failure. TAC is a surgical procedure which constricts a targeted region of the aortic arch, simulating pressure overload seen in human conditions like aortic stenosis. TAC surgery induces initial compensation hypertrophy, associated with temporary enhancement of cardiac contractility, followed by progressive left ventricular dilation and hypertrophy, resulting in eventual heart failure. This progression allows for the study of both Heart Failure with Reduced Ejection Fraction (HFrEF) and Heart Failure with Preserved Ejection Fraction (HFpEF).  

Recognized as the gold standard in preclinical cardiac research, the gradual and reproducible development of cardiac hypertrophy in the TAC mouse model facilitates longitudinal studies, making it an ideal model for assessing drug efficacy in heart failure interventions. InnoSer’s skilled surgical team conducts TAC procedures with high precision and expertise, ensuring consistent and reproducible outcomes for your research. Contact our expert team today to discuss how the TAC mouse model can support your preclinical research into heart failure interventions.  

✓  Gold-standard surgical mouse model of cardiac hypertrophy and associated heart failure 

✓  TAC leads to left ventricular dilation and hypertrophy.

✓  Model can be used to study both HFrEF and HFpEF  

Transverse Aortic Constriction mouse model

As a preclinical cardiovascular CRO, InnoSer works with multiple validated research models of common cardiovascular diseases. To study hypertension-associated cardiovascular dysfunction and heart failure, InnoSer offers Angiotensin II-induced hypertension mouse model.  

InnoSer’s specialised facilities and trained personnel equipped for reliable execution of technical cardiac surgeries and other functional procedures allows for possibility to run studies using models of myocardial infarction using LAD and/or ischemia/reperfusion mouse models. Reach out to our team to learn more about possibility of running other cardiovascular disease-related models.  

TAC Mouse Model Sample Data

TAC Mouse Model Readouts

Key TAC mouse model readouts that InnoSer offers


Test the efficacy of your treatments in the following battery of translational readouts:
    • Echocardiography left ventricular function
    • Cardiac hypertrophy
    • Fibrosis and remodelling
    • Lung congestion

    The People Behind Your Research

    Yanick Fanton, PhD, Chief Scientific Officer

    As Chief Science Officer at InnoSer, Yanick is responsible for all customer studies at InnoSer and takes care of the scientific and technical coordination.

    Stay Curious: More Articles to Explore

    Latest cardiovascular and metabolic research news

    Latest cardiovascular and metabolic research news

    InnoSer offers a selection of gold standard cardio-metabolic disease models in rodents, supporting custom studies to optimize the preclinical development of your drug candidates. Learn more about you can leverage InnoSer’s experience and expertise in the cardio and...

    AAALAC Accreditation

    InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.

    AAALAC logo

    Animal Welfare

    The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.